NEOLEUKIN THERAPEUTICS NLTX 深 沪
已收盘 12-18 16:00:00 美东时间
3.49
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 3.49
- 总市值 3073.05万
- 52周最高 18.80
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 8.30
- 委 比 0.00%
- 总股本 880.53万
- 历史最高 362.60
- 量 比 0
- 振 幅 0.00%
- 历史最低 7.50
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Neurogene downgraded to Neutral at Baird on regulatory uncertainty
Neurogene (NASDAQ:NGNE) was downgraded to Neutral from Outperform at Baird, citing increasing regulatory uncertainty and a higher approval bar at the FDA under new leadership. The analysts at Baird sa...
05-16 23:18
Neoleukin Therapeutics reports FY results
Neoleukin Therapeutics press release (NASDAQ:NGNE): FY Revenue of $0.93M beats by $0.16M. Net income for the twelve months ended December 31, 2023 included a one-time $16.4 million bargain purchase ga...
03-25 04:24
Neurogene and Ventyx Biosciences rises after insider buying by executives
Shares of Neurogene (NASDAQ:NGNE) and Ventyx Biosciences (NASDAQ:VTYX) rose after both reported executive insider buys in recent SEC Filings. According to the filing from November 25, Neurogene’s CFO ...
2024-11-27 01:15
Neurogene GAAP EPS of -$1.19 in-line
Neurogene press release (NASDAQ:NGNE): Q3 GAAP EPS of -$1.19 in-line. Cash, cash equivalents and investments as of September 30, 2024 were $139.0 million. The company continues to expect current cash,...
2024-11-19 14:55
Neurogene stock plunges 36% on NGN-401 study update
Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy NGN-401 for Rhett syndrome. Neurogene (NGNE) said that a patient who had b...
2024-11-18 22:53
Neurogene a new outperform at Baird on gene therapy for Rett syndrome
Baird started Neurogene (NASDAQ:NGNE) off at outperform as its Rett syndrome candidate, NGN-401, has shown promise with early data and the asset was recently selected by the U.S. FDA for a pilot progr...
2024-06-11 23:02
Neoleukin Therapeutics GAAP EPS of -$1.00 beats by $0.03
Neoleukin Therapeutics press release (NASDAQ:NGNE): Q1 GAAP EPS of -$1.00 beats by $0.03. Cash, cash equivalents and investments as of March 31, 2024 were $169.5 million. The Company expects current c...
2024-05-10 19:46
89bio Appoints Biotech Industry Veteran, Martin Babler to Its Board of Directors
SAN FRANCISCO, April 17, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasd...
2024-04-18 04:05
Neoleukin Therapeutics Plans 1-For-5 Reverse Stock Split
The reverse stock split will become effective at 12:01 a.m. Eastern time on September 25, 2023.
2023-09-22 20:03
